In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.

Abstract

The in vitro activity of S-25930 and S-25932, two new 4-quinolones, against 450 aerobic gram-negative organisms isolated from cancer patients was evaluated and compared with the activity of ciprofloxacin, enoxacin, difloxacin (A-56619), and A-56620. Both agents inhibited most members of the family Enterobacteriaceae at concentrations of less than or equal to 2.0 micrograms/ml, but their activity against Pseudomonas aeruginosa was inferior to that of other quinolones. Although considerably less active than ciprofloxacin and A-56620, S-25930 was frequently two- to eightfold more active than S-25932 and was comparable to difloxacin and enoxacin against most isolates.

• Authors: K V Rolston, D H Ho, B LeBlanc, G P Bodey
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 31 Issue 1 Pg. 102-3 (Jan 1987) ISSN: 0066-4804 [Print] United States
• PMID: 3471177 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Fluoroquinolones
• Naphthyridines
• Quinolizines
• Enoxacin
• ibafloxacin
• Ciprofloxacin
• difloxacin
• S 25932
• sarafloxacin

Topics

• Anti-Bacterial Agents (pharmacology)
• Bacterial Infections (complications, microbiology)
• Ciprofloxacin (analogs & derivatives, pharmacology)
• Enoxacin
• Fluoroquinolones
• Gram-Negative Bacteria (drug effects)
• Humans
• Naphthyridines (pharmacology)
• Neoplasms (complications)
• Quinolizines (pharmacology)